List of Morphabond Er drug patents

Morphabond Er is owned by Daiichi Sankyo Inc.

Morphabond Er contains Morphine Sulfate.

Morphabond Er has a total of 2 drug patents out of which 0 drug patents have expired.

Morphabond Er was authorised for market use on 02 October, 2015.

Morphabond Er is available in tablet, extended release;oral dosage forms.

The generics of Morphabond Er are possible to be released after 12 August, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314788 DAIICHI SANKYO INC Pharmaceutical compositions configured to deter dosage form splitting
Aug, 2028

(5 years from now)

US7955619 DAIICHI SANKYO INC Abuse resistant drugs, method of use and method of making
Aug, 2028

(5 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 02 October, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MORPHABOND ER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic